ライフサイエンスコーパス: thromboembolic

1 e evidence that most cryptogenic strokes are thromboembolic.

2 Adverse events of interest were thromboembolic adverse events (six [7%] patients receivi

3 Thromboembolic adverse events were reported in 153 patie

4 Eleven thromboembolic adverse events were reported in 9 of 295

5 be associated with increased risks of venous thromboembolic and arterial disease.

6 the incidence of first and recurrent venous thromboembolic and arterial events.

7 alves was associated with increased rates of thromboembolic and bleeding complications, as compared w

8 also analyzed (cross-allergies, frequency of thromboembolic and bleeding complications, HIT, and preg

9 ment of 252 patients because of an excess of thromboembolic and bleeding events among patients in the

10 the rhythm-control group, P=0.61), including thromboembolic and bleeding events.

11 fection is associated with increased risk of thromboembolic and cardiovascular comorbid conditions.

12 arfarin therapy in preventing periprocedural thromboembolic and hemorrhagic events after radiofrequen

13 Periprocedural thromboembolic and hemorrhagic events are worrisome comp

14 ssociated with a transient increased risk of thromboembolic and hemorrhagic events.

15 her mortality from surgical site, pulmonary, thromboembolic, and other complications.

16 In vivo, in rats subjected to thromboembolic brain ischemia, we found that intraischem

17 ith a nuclear ventilation/perfusion scan for thromboembolic causes of PH.

18 ke that combines high age and tauopathy with thromboembolic cerebral ischemia.

19 The only thromboembolic complication was transient ischemic attac

20 to explore the incidence and risk factors of thromboembolic complications after cardioversion of acut

21 associated with a significant risk of venous thromboembolic complications and medical resource consum

22 There were no thromboembolic complications and no deaths in either gro

23 ral history of IDDVTs and their real risk of thromboembolic complications are still uncertain because

24 s been less successful, in large part due to thromboembolic complications associated with anti-CD154

25 complications associated with LHRHa and the thromboembolic complications associated with oral oestro

26 e environments in mediating life-threatening thromboembolic complications associated with shear-media

27 egy is essential for minimizing bleeding and thromboembolic complications during and after AF ablatio

28 Thromboembolic complications following major abdominal s

29 e Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARI

30 The incidence of post-cardioversion thromboembolic complications is high in certain subgroup

31 athy that serves as the substrate for AF and thromboembolic complications might improve treatment out

32 In children, thromboembolic complications occur about 7 times less of

33 is associated with better survival and lower thromboembolic complications than UH.

34 k between AF and brain injury extends beyond thromboembolic complications to include a cardiovasculop

35 of those patients experienced early arterial thromboembolic complications vs 9 of 584 control patient

36 The absolute risk of thromboembolic complications was higher among patients w

37 Major surgical and thromboembolic complications were rare and did not diffe

38 Total hemorrhagic and thromboembolic complications were similar in both groups

39 The treatment and prevention of thromboembolic complications will also be addressed.

40 ents with intravascular coagulation (DIC and thromboembolic complications) as shown by sP-selectin an

41 erative events, wound, pulmonary, and venous thromboembolic complications, and urinary tract infectio

42 cardiovascular (CV) sequelae, which include thromboembolic complications, cardiac, and vascular toxi

43 dent protective factor against mortality and thromboembolic complications, regardless of timing of pr

44 ntravascular coagulation (DIC) and recording thromboembolic complications.

45 nferior to fondaparinux in the prevention of thromboembolic complications.

46 Outcomes were death, disability, and thromboembolic complications.

47 monary and overall morbidity, infection, and thromboembolic complications.

48 of hypercoagulability and confers a risk of thromboembolic complications.

49 hose at low risk of bleeding or high risk of thromboembolic complications.

50 n the pathogenesis of AF and its age-related thromboembolic complications.

51 electric activity to atrial standstill; (4) thromboembolic complications; and (5) stable, normal lef

52 Anticoagulation reduces thromboembolic complications; the newer anticoagulants h

53 Thromboembolic conditions are divided into arterial and

54 Thromboembolic conditions were estimated to account for

55 IPC was also more effective than thromboembolic deterrent stockings in reducing deep vein

56 IPC with pharmacological thromboprophylaxis, thromboembolic deterrent stockings, no prophylaxis, and

57 The etiology of pediatric venous thromboembolic disease (VTE) is multifactorial, and in m

58 uring 2012, observed rates of stroke, venous thromboembolic disease (VTE), and heart failure were low

59 gate whether SSPE forms a distinct subset of thromboembolic disease compared with more proximally loc

60 assay that enables urinary discrimination of thromboembolic disease in mice using doses of the nanopa

61 Thromboembolic disease is a leading cause of morbidity a

62 The diagnosis of deep venous thromboembolic disease is still challenging despite the

63 Thromboembolic disease is the most frequent medical comp

64 ould make interesting therapeutic targets in thromboembolic disease, atherosclerosis, sepsis, autoimm

65 many pathological conditions, including the thromboembolic disease, cancer and neurodegenerative dis

66 eft heart disease, lung disease, and chronic thromboembolic disease.

67 off-label clinical application in pediatric thromboembolic disease.

68 n within STXBP5 is a genetic risk for venous thromboembolic disease.

69 ther conditions such as connective tissue or thromboembolic disease.

70 ation, recurrent infections, and angiopathic thromboembolic disease; the disorder followed an autosom

71 Thromboembolic diseases such as myocardial infarction, s

72 have a significant role in the treatment of thromboembolic diseases--a leading cause of patient morb

73 e been found effective in treating different thromboembolic diseases.

74 e been the standard of care for treatment of thromboembolic diseases.

75 oral anticoagulant used in the management of thromboembolic disorders for over 60 years.

76 hibition may offer a safe strategy to combat thromboembolic disorders including ischemic stroke.

77 The medical and socioeconomic relevance of thromboembolic disorders promotes an ongoing effort to d

78 atients were included who accounted for 1858 thromboembolic emergencies (48 per month) during the 3-y

79 during the 3-year Baseline interval and 1077 thromboembolic emergencies (83 per month) during the 1-y

80 ositis (none vs four [10%] vs one [3%]), and thromboembolic event (none vs three [8%] vs two [5%]).

81 e aortic insufficiency (P=0.078) but not for thromboembolic event (P=0.638).

82 There was one grade 3 thromboembolic event in the combination arm and one inte

83 nths in patients experiencing a first venous thromboembolic event in the setting of major, transient

84 g the first cycle of therapy, and one venous thromboembolic event occurred during the study.

85 A single thromboembolic event occurred in each of the dabigatran

86 Thromboembolic event rates differed markedly in non-anti

87 We explored the variation in thromboembolic event rates in a non-anticoagulated AF po

88 sient ischemic attack (TIA), or a peripheral thromboembolic event were randomly assigned to undergo c

89 diagnosis and seven of those had documented thromboembolic event while on extracorporeal membrane ox

90 lower risk of coronary heart disease, venous thromboembolic event, and cerebrovascular disease than i

91 ents (AEs), such as intracranial hemorrhage, thromboembolic event, and progressive aortic insufficien

92 d up to the time of intracranial hemorrhage, thromboembolic event, or progressive aortic insufficienc

93 (survival free of any nonsurgical bleeding, thromboembolic event, pump thrombosis, or neurological e

94 ascular event, and 14,550 had a first venous thromboembolic event.

95 ntation, new heart failure, stroke, or other thromboembolic event.

96 hemopericardium, and 5 patients (0.7%) had a thromboembolic event.

97 lder age, smoking, node negativity, or prior thromboembolic event.

98 anticoagulated patients experienced nonfatal thromboembolic events (1.1%/year), whereas 13 with apica

99 arrhoea (nine [7%] vs nine [7%]), and venous thromboembolic events (11 [8%] vs six [4%]).

100 years; 30 of the patients (20%) developed 32 thromboembolic events (15 arterial and 17 venous events)

101 readmissions, followed by cardiovascular or thromboembolic events (18%).

102 [2%] patients), and grade 3 or higher venous thromboembolic events (23 [8%] vs 11 [4%] patients) than

103 There were 39 thromboembolic events (3.7% strokes [n=29] and 1.3% tran

104 idence interval [CI]: 0.5% to 1.0%) definite thromboembolic events (31 strokes) within 30 days (media

105 had little impact on the findings for venous thromboembolic events (431 [0.9%] versus 461 [1.0%], OR

106 Rates of thromboembolic events (6%) and hepatobiliary adverse eve

107 g muscles and/or joints (8/11), vascular and thromboembolic events (6/11), that is, deep vein thrombo

108 r complications (8.6% vs 0.1%; P=0.037), and thromboembolic events (8.6% vs 6.0%; P=0.037) were highe

109 vents, but focused on the subset of arterial thromboembolic events (ATEs), comprising CV death, myoca

110 nced grade 3 to 4 toxicity, and 10 (20%) had thromboembolic events (deep venous thrombosis or pulmona

111 and nonsignificant lower risk of stroke and thromboembolic events (odds ratio =0.61, 95% confidence

112 erebrovascular disease (P<0.001), and venous thromboembolic events (P<0.001) than those reporting doi

113 Thrombotic/thromboembolic events (TEE) have been reported with plas

114 ied a boxed safety warning about the risk of thromboembolic events (TEEs), with TEEs reported in 0.5%

115 e predictive value of stroke risk scores for thromboembolic events (TEs) after catheter ablation of a

116 is are associated with lower rates of venous thromboembolic events (VTE), major bleeding, and superfi

117 ality, stroke, myocardial infarction, venous thromboembolic events (VTEs), and hypertension.

118 ty, accounts for the highest rates of venous thromboembolic events (VTEs).

119 requirements without increasing the risk of thromboembolic events across a wide variety of liver tra

120 the incidence of LAA thrombus formation and thromboembolic events after LAAI.

121 Three thromboembolic events and 1 major bleeding event occurre

122 The safety outcomes were thromboembolic events and all-cause mortality within 30

123 , patients with paroxysmal AF suffered fewer thromboembolic events and deaths compared with those wit

124 optical density; had a higher prevalence of thromboembolic events and reached platelet count nadir l

125 Data regarding the risk of thromboembolic events and stroke after LAAI are sparse.

126 ma samples obtained from patients with prior thromboembolic events are denser and less susceptible to

127 Prophylaxis against and treatment of thromboembolic events are necessary and should consider

128 Patients with AF also may have thromboembolic events at higher INR levels.

129 ing or thromboembolism, patients with AF had thromboembolic events at higher international normalized

130 essment must address each patient's risk for thromboembolic events balanced against the risk for peri

131 There were no differences in thromboembolic events between the groups (22 [6.0%] vs 3

132 diagnostic strategy, defined as adjudicated thromboembolic events during the 3-month follow-up perio

133 o evaluate the previously reported excess of thromboembolic events during the 30 days after the end o

134 stroke and non-central nervous system (CNS) thromboembolic events early after discontinuation of riv

135 There was a higher incidence of thromboembolic events for the transfusion threshold of 1

136 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

137 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

138 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

139 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

140 d Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)

141 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARIS

142 e Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial who r

143 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.

144 (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.

145 systematically identified symptomatic venous thromboembolic events in both trials.

146 a-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.

147 Consequently, the prevention of thromboembolic events in LA positives might improve surv

148 b and bevacizumab may contribute to systemic thromboembolic events in patients aged 65 years or older

149 egarding the effectiveness and occurrence of thromboembolic events in patients treated with prothromb

150 e and efficacious in preventing bleeding and thromboembolic events in patients undergoing AF ablation

151 E constituted 11.5% of clinically recognized thromboembolic events in patients with atrial fibrillati

152 erapy is the standard therapy for preventing thromboembolic events in patients with atrial fibrillati

153 Diabetes is a known risk predictor for thromboembolic events in patients with atrial fibrillati

154 Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, ir

155 rophylactic anticoagulation and treatment of thromboembolic events in patients with hepatic insuffici

156 of thrombus formation leading to significant thromboembolic events in patients with nonvalvular atria

157 The incidence of thromboembolic events in the 48 hours after ablation was

158 30) and trend toward more cardiovascular and thromboembolic events in the NCRT group (P=0.069).

159 es, but tamoxifen increased the incidence of thromboembolic events more than raloxifene by 4 cases in

160 Thromboembolic events occurred in 4 subjects receiving d

161 Thromboembolic events occurred in one patient receiving

162 ring days 1-720, ten (1.2% per patient year) thromboembolic events occurred in the Fiix-PT group vers

163 Three thromboembolic events occurred within 3 days (one in the

164 mly assigned patients with an annual risk of thromboembolic events of 5% or more to continued warfari

165 ertension of grade 2 or higher (25% vs. 2%), thromboembolic events of grade 3 or higher (8% vs. 1%),

166 Thromboembolic events on dabigatran led to early termina

167 There was no difference in rates of thromboembolic events or other complications between the

168 ere were 0.75 major bleeding events and 0.28 thromboembolic events per patient year of follow-up.

169 Emergency visits for thromboembolic events spanning 1-4 years before treatmen

170 ial fibrillation (AF) have increased risk of thromboembolic events such as stroke and myocardial infa

171 nd atrial fibrillation are at higher risk of thromboembolic events than patients with heart failure a

172 i-Platelet Trialists' Collaboration arterial thromboembolic events through W96.

173 f hospitalizations for bleeding and arterial thromboembolic events were estimated in an intent-to-tre

174 events and 33 and 58 and 12 and 28 arterial thromboembolic events were observed during follow-up, re

175 No thromboembolic events were observed during the study.

176 Arterial thromboembolic events were reported in 5.6% of the patie

177 Thromboembolic events were significantly increased with

178 Thromboembolic events were the likely cause of various c

179 hagic and ischemic stroke, or between venous thromboembolic events with or without pulmonary embolism

180 ricular arrhythmias, 5 cardiac deaths, and 5 thromboembolic events).

181 rotocol-defined withdrawal criteria (11 [4%] thromboembolic events, 5 [2%] exceeding liver enzyme thr

182 site endpoint of HIT-specific complications (thromboembolic events, amputation, skin necrosis) occurr

183 including severe heart failure, arrhythmias, thromboembolic events, and death, the majority of women

184 afety end point was a composite of bleeding, thromboembolic events, and death.

185 ile (adverse events, serious adverse events, thromboembolic events, and deaths) was similar between g

186 as not apparent for emergencies unrelated to thromboembolic events, and did not occur in a control gr

187 Gastrointestinal side effects, hot flashes, thromboembolic events, and infections vary among drugs.

188 h) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular even

189 ment-related deaths, second primary cancers, thromboembolic events, and peripheral neuropathy.

190 heart failure, hospitalization, arrhythmia, thromboembolic events, and reintervention).

191 im of this study was to compare the risk for thromboembolic events, bleeding, and mortality associate

192 arboplatin, as were hypertension, infection, thromboembolic events, bleeding, and postoperative compl

193 hospitalization, but no increase in risks of thromboembolic events, bleeding-related hospitalization,

194 d thrombin activity underlies obesity-linked thromboembolic events, but the mechanistic links between

195 ble electronic devices and increased risk of thromboembolic events, clinical intervention for device-

196 here show that systemic hypoxia accelerates thromboembolic events, functionally stimulated by the ac

197 For patients at high risk for thromboembolic events, guidelines recommend bridging the

198 ll as 2-year risk of death, hospitalization, thromboembolic events, heart failure (HF), and AF progre

199 Outcome was a composite of thromboembolic events, heart failure hospitalizations, v

200 e modest increases in rates of hypertension, thromboembolic events, intestinal perforation, and neutr

201 levant safety end points, including arterial thromboembolic events, MI, stroke or transient ischemic

202 ase duration; hemoglobin level; frequency of thromboembolic events, palpable splenomegaly, and splene

203 e frequent clinical complications, including thromboembolic events, seizures, fluctuations in neurolo

204 had lower risk-adjusted all-cause mortality, thromboembolic events, subsequent depression, alcoholism

205 s finding the optimal equilibrium to prevent thromboembolic events, such as stent thrombosis and thro

206 No thrombotic or thromboembolic events, systemic allergic reactions (incl

207 center, PREFER in AF (European Prevention of thromboembolic events-European Registry in Atrial Fibril

208 higher incidence of both venous and arterial thromboembolic events.

209 ted, including all-cause mortality and fatal thromboembolic events.

210 associated complications of arrhythmias and thromboembolic events.

211 bleeding risk without a favorable effect on thromboembolic events.

212 ular atrial fibrillation is a major cause of thromboembolic events.

213 ), thresholds were stable, and there were no thromboembolic events.

214 pathogenesis of atherosclerosis, leading to thromboembolic events.

215 lation has been associated with some risk of thromboembolic events.

216 long-term survival and very low incidence of thromboembolic events.

217 and fractures and increased the incidence of thromboembolic events.

218 with respect to the incidence of bleeding or thromboembolic events.

219 rophylaxis do not have an increased risk for thromboembolic events.

220 al relevance in prophylaxis and treatment of thromboembolic events.

221 f statins (or higher dose statins) on venous thromboembolic events.

222 at high risk for arrhythmic sudden death and thromboembolic events.

223 ves during pregnancy is essential to prevent thromboembolic events.

224 carotid artery stenting reduces the rate of thromboembolic events.

225 s, non-O blood groups explain >30% of venous thromboembolic events.

226 0.88; 95% confidence interval, 0.64-1.21) or thromboembolic (hazard ratio, 1.10; 95% confidence inter

227 latform for further study of a translational thromboembolic model of acute ischemic stroke.

228 are characterized by rapid onset of multiple thromboembolic occlusions affecting diverse vascular bed

229 risk of death and hospitalizations, but not thromboembolic or bleeding events.

230 is not associated with additional benefit in thromboembolic or coronary risk, but notably increased b

231 ound no evidence to suggest a higher risk of thromboembolic or hemorrhagic complications with use of

232 lure, ventricular arrhythmias, heart blocks, thromboembolic phenomena, and sudden death.

233 tic balloon pump being in situ, and possible thromboembolic phenomena.

234 The use of antibiotic and thromboembolic prophylaxis in elective laparoscopic chol

235 stance indicated severe or nonsevere chronic thromboembolic pulmonary hypertension (> 900 or </= 900

236 The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmon

237 Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare

238 Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare,

239 els was assessed in 34 patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing

240 Chronic thromboembolic pulmonary hypertension (CTEPH) was confir

241 g of the pathophysiological basis of chronic thromboembolic pulmonary hypertension (CTEPH) will be ac

242 Patients with severe chronic thromboembolic pulmonary hypertension (n = 15) had highe

243 respiratory disease (n = 41; 18%); group IV, thromboembolic pulmonary hypertension (n = 2; 1%); or gr

244 patients at higher risk of dying of chronic thromboembolic pulmonary hypertension and identifies a l

245 arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension and impaired right

246 vascular resistance in patients with chronic thromboembolic pulmonary hypertension by high temporal r

247 ssigned 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or r

248 Chronic thromboembolic pulmonary hypertension results from incom

249 A total of 19 patients with chronic thromboembolic pulmonary hypertension underwent right he

250 ard-approved study, 20 patients with chronic thromboembolic pulmonary hypertension were examined at 1

251 of 679 patients newly diagnosed with chronic thromboembolic pulmonary hypertension were prospectively

252 utable to right ventricular failure (chronic thromboembolic pulmonary hypertension).

253 Chronic thromboembolic pulmonary hypertension, a rare complicati

254 are pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and pulmonary hyp

255 patients who are inoperable and have chronic thromboembolic pulmonary hypertension, riociguat, a stim

256 For patients with chronic thromboembolic pulmonary hypertension, surgical pulmonar

257 d and not-operated patients who have chronic thromboembolic pulmonary hypertension.

258 to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension.

259 monary hemodynamics in patients with chronic thromboembolic pulmonary hypertension.

260 monary hemodynamics in patients with chronic thromboembolic pulmonary hypertension.

261 tion of pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.

262 vascular resistance in patients with chronic thromboembolic pulmonary hypertension.

263 with severe compared with nonsevere chronic thromboembolic pulmonary hypertension.

264 ean age, 57 years) underwent PEA for chronic thromboembolic pulmonary hypertension.

265 pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensive disease patients.

266 both conditions results in a higher risk for thromboembolic-related adverse events but a paradoxical

267 ound disruption, cardiac/transfusion, venous thromboembolic, renal, and neurological complications, a

268 outpatients with AF and intermediate to high thromboembolic risk (CHADS2 score >/=2 and CHA2DS2-VASc

269 The period in which thromboembolic risk abates remains uncertain, and trials

270 s ruled out, in regards of the prevalence of thromboembolic risk factors and the 3-month risks of rec

271 not exclusively, to the overall increase of thromboembolic risk in AF.

272 linical score originally designed to predict thromboembolic risk in atrial fibrillation (AF; CHA2DS2-

273 role of insulin versus no insulin therapy on thromboembolic risk in patients with diabetes and AF.

274 Although thromboembolic risk is currently defined by clinical sco

275 redictable anticoagulation response, whereas thromboembolic risk prediction scores such as CHADS2 (Ca

276 2-VASc score instead of the CHADS2 score for thromboembolic risk stratification and initiation of ora

277 No significant difference in thromboembolic risk was observed for TT versus VKA+antip

278 We highlight the increased thromboembolic risk with coexisting AF and type 2 diabet

279 ex category) score, incompletely account for thromboembolic risk, and emerging evidence suggests that

280 For transgender women, CSHT has known thromboembolic risk, and lower-dose transdermal estrogen

281 ontinuation seem to be associated with lower thromboembolic risk, no randomized study exists.

282 important variable in the stratification of thromboembolic risk, particularly in patients with nonva

283 atrial dilatation with standstill evolution, thromboembolic risk, preserved left ventricular function

284 atio of 2 to 3 or 2.5 to 3.5 on the basis of thromboembolic risk.

285 hed controls and investigated their relative thromboembolic risk.

286 requiring insulin did not imply an increased thromboembolic risk.

287 loss of LAA mechanical function may increase thromboembolic risk.

288 ble effectiveness and concerns regarding its thromboembolic risks.

289 udy sample coming from our GWAS on pediatric thromboembolic stroke (combined P = 7.88 x 10(-7)).

290 Following thromboembolic stroke bexarotene enhanced autophagy in t

291 Although AF is known to increase the risk of thromboembolic stroke from the left atrium (LA), the exa

292 deaths due to hemorrhagic complications and thromboembolic stroke in clinics worldwide.

293 Thus, in a new large-vessel thromboembolic stroke model in mice, this cotreatment si

294 traumatic brain injury, postcraniotomy, and thromboembolic stroke patients, whereas gabapentin/prega

295 embolic events, such as stent thrombosis and thromboembolic stroke, without increasing bleeding risk.

296 progression-free survival (PFS; overall) and thromboembolic (TE) event rate.

297 he incidences of HIT-specific complications (thromboembolic venous/arterial events, amputations, recu

298 ion, the study of the epidemiology of venous thromboembolic (VTE) complications in SCD is only now be

299 are at high risk for life-threatening venous thromboembolic (VTE) events.

300 to assess the presence and extent of venous thromboembolic (VTE) surveillance bias using high-qualit